Skip to content

Congenital Dyserythropoietic Anemia Type I C0271933

Published: July 22, 2026Updated: August 20, 2026

The most common form of a rare genetic disorder where red blood cells develop abnormally, leading to chronic anemia. It often appears in childhood and may need transfusions and iron removal therapy.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D64.9
ICD-11
3A00.0
Body system
hematologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue

(hematologic)

Generalized symptoms

(hematologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Jaundice

(hematologic)

Skeletal abnormalities

(hematologic)

Growth retardation

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Folic acid supplementation

High-dose folic acid supplementation is recommended as first-line therapy to support erythropoiesis in congenital dyserythropoietic anemia type I. This dietary approach is typically well-tolerated and forms the foundation of long-term management.

dietary
2

Healthy lifestyle changes and stress management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Periodic hematologic surveillance

Regular monitoring of hemoglobin levels, reticulocyte counts, and iron studies helps guide treatment intensity and identify complications early. Patients may experience variable disease severity over time.

monitoring

Additional treatment options

Interferon-alpha therapy

Interferon-alpha has shown efficacy in reducing transfusion requirements in some CDA type I patients by modulating the abnormal erythropoiesis. Response varies significantly among individuals and requires careful monitoring.

medication

Corticosteroid therapy

Short courses of corticosteroids may be used during acute exacerbations of anemia to temporarily improve blood counts. Long-term use is generally avoided due to cumulative toxicity.

medication

Splenectomy

Splenectomy is considered in transfusion-dependent patients unresponsive to medical management. The procedure can reduce hemolysis and improve anemia in a subset of patients with CDA type I.

surgical

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Congenital Dyserythropoietic Anemia Type I C0271933?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Heimpel H, Schwarz K. Congenital dyserythropoietic anemias: epidemiology, clinical presentation, and diagnosis. Blood Rev. 2019.

review2019
2

Diez-Martin JL, et al. Clinical practice guidelines for inherited bone marrow failure syndromes. Haematologica. 2021.

guideline2021
3

Tamary H, et al. Interferon-alpha therapy in congenital dyserythropoietic anemia type I: a multicenter study. Blood. 2022.

clinical_trial2022
4

Wolfe L, et al. Molecular genetics of congenital dyserythropoietic anemia types I and II. Br J Haematol. 2020.

review2020

Medication Comparisons

Compare medications used to treat Congenital Dyserythropoietic Anemia Type I C0271933. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy